Introduction
Epigenetic marks such as histone modifications and DNA methylation are involved in cell memory expression patterns which are transmitted through cell division (1) .
Chromatin modifications are required in all organisms while DNA methylation is not present in some lower organisms like worms and flies, suggesting that chromatin has a broader epigenetic function in gene regulation (1) . Histone acetylation is associated with open chromatin and gene expression while removal of acetyl groups by histone deacetylases is observed in inactive chromatin. In higher organisms, DNA methylation plays an important role in several physiological processes, including X chromosome inactivation, genomic imprinting, silencing of germ cell specific genes and repetitive elements (2) . In cancer, tumor suppressor genes (TSG) are silenced by both DNA hypermethylation and chromatin repressive marks (2, 3) .
A common hypothesis is that DNA methylation serves as a «molecular lock» that prevents reprogramming and is responsible for stable gene silencing (1, 4, 5) . This concept was built on indirect observations whereby hypermethylated genes in cancer cells could be reactivated only after removal of promoter DNA hypermethylation using hypomethylating drugs such as decitabine (5-aza-2'-deoxycytidine, 5-AZA-CdR). By contrast chromatin acetylation induced by histone deacetylase inhibitors (HDACi) such as Trichostatin A (TSA) could not reactivate hypermethylated genes in cancer cells (6) (7) (8) .
However, more recently some reports have shown that HDACi such as TSA and depsipeptide (Depsi) produce gene reactivation from hypermethylated promoters without any changes in DNA methylation at the promoter level (9) (10) (11) (12) . Since these reports were against the current paradigm, a more detailed look at this issue was needed. Author Manuscript Published OnlineFirst on January 4, 2012; DOI: 10.1158/0008-5472. One of the problems in studying DNA methylation-associated silencing of TSG is that reactivation of these genes can impair cellular growth and be difficult to detect and quantitate. A selectable system was recently described to overcome this issue. YB5 cells are derived from the SW48 colon cancer cell line transfected with a green fluorescent protein (GFP) driven by a hypermethylated cytomegalovirus (CMV) promoter packaged into inactive chromatin. YB5 carries a single copy of CMV/GFP stably integrated in chromosome 1. GFP can be reactivated in YB5 cells by treatment with 5-AZA-CdR when its promoter region is demethylated and also marked by active chromatin signals characterized by H3K9 acetylation, low level of H3K27 trimethylation and low nucleosome density (13) .
In this paper, we use YB5 cells (and 5 other cancer cell lines) to show that the vast majority of HDACi tested can reactivate genes silenced by promoter hypermethylation without detectable changes in DNA methylation. We further show that while DNA methylation cannot prevent gene activation by chromatin reprogramming, it is essential for long-term gene silencing. 
Materials and Methods

Cell culture and drug treatments
All cell lines were obtained from American Type Culture Collection. Cell lines were authenticated at MD Anderson Cancer Center with short tandem repeat PCR method.
YB5 cell line is a colon cancer cell line generated from SW48 as previously described (13) . YB5 cell line was cultured in L-15 medium while MCF-7, K562, MDA-MD-231, and PC-3 cells were cultured in RPMI 1640. Both cell culture media contained 10% fetal bovine serum and 100 μg/mL Penicillin-Streptomycin solution. Cells growing in log phase were treated with decitabine (5-AZA-CdR) at 50 nM for 72h. Drug and medium were replaced every day. Cells were cultured an additional 24h without drug prior to analysis. HDAC inhibitors (HDACi) were dissolved either in DMSO, ethanol or PBS according the manufacturers' recommendations. HDACi were added for 24h at various concentrations prior to analysis.
Histone extraction and Western blots
Total protein extracts were prepared using RIPA buffer as described previously (14) in the presence of sodium butyrate (5 mM) to avoid in vitro histone deacetylation and resolved on 15% SDS-polyacrylamide gels. Antibodies used were H3K9-acetylation (07-352 Millipore), H4K16-acetylation (39168, Active motif) and total H3 (ab1791 Abcam). Author Manuscript Published OnlineFirst on January 4, 2012; DOI: 10.1158/0008-5472. analyzed using Kaluza ® software. GFP cell sorting was performed using BD FACSAriaII. GFP fluorescence of samples was analyzed post-sorting to assess the purity of the sorted cells.
RNA extraction, cDNA synthesis, quantitative real-time PCR
Total RNA (2 μg) was extracted using Trizol (Invitrogen) and cDNA was synthesized using High-Capacity cDNA Kit (Applied Biosystems). Quantification of cDNA was done by qPCR with the Universal PCR Master Mix (Bio-Rad) using ABI Prism 7900HT.
Results were obtained from at least three independent experiments where each sample was analyzed in duplicate. 18S was used as a reference gene. cDNA synthesis used the same amount of RNA after treatment with different drugs. All primers, except GFP primers that were described previously (13) , are listed in supplemental Table S1 . 5′ Rapid amplification of cDNA ends (5′-RACE) was done as previously described (13) .
DNA extraction and DNA methylation analysis
DNA extraction and bisulfite conversion, pyrosequencing and bisulfite cloning/sequencing were carried out as previously described (13) . All primers are listed in supplemental Table S1 , except for all GFP primers that were described previously (13) .
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously (14) . Antibodies used were anti-histone 
Gene expression and DNA methylation microarrays
Gene expression analysis was performed using the Agilent whole genome array (G4112F) that was scanned using the Agilent G2505B scanner. Data represents the average expression level of two independent experiments. DNA methylation analysis using high-throughput methylation profiling by MCA coupled to CpG island microarray (MCAM) was performed as described previously (15) . After analysis, genes with M values more than 1.3 were considered methylated. Microarray data sets were deposited in the Gene Expression Omnibus (GEO) database with the accession number GSE34077.
Statistical analysis
Differences between groups were assessed using a t-test. A 2-sided P value of 0.05 was considered statistically significant. 1A ), quantified by FACS analysis (Fig. 1B) , and associated with extensive global histone acetylation (Fig. 1C) . HDACi produced GFP mRNA and GFP fluorescence as early as 12h after treatment ( Figure S1 A-B). GFP reactivation was not specific to a molecular structure or chemical class of these epigenetic drugs since the vast majority of HDACi tested activated this hypermethylated locus ( Fig. 1D and Table 1 ). Moreover, GFP fluorescence and mRNA levels were stronger after a 24h treatment with HDACi than after a 72h treatment with 5-AZA-CdR ( Fig. 1D-E) . We confirmed by 5'RACE experiments that GFP mRNA originated from its own promoter and not from an alternative transcription start site (data not shown).
It has previously been suggested that HDACi can lead to DNA demethylation (16) (17) (18) .
To test this, DNA methylation levels were measured after treatment with 7 different 4A-D) . Interestingly, we recently reported that regardless of DNA methylation status, gene reactivation is associated with a promoter region marked by active chromatin marks and low nucleosome density (13) . Following Depsi treatment, all promoter regions of GFP, CDH13, MLH1, and WIF-1 showed an increase in activating marks (1.5 to 24.5 fold) such as H3K9-Ac (Fig. 4A ), H3K4-me3 (Fig. 4B) , and H3K36-me3 (Fig. 4C) . By contrast, H3K27-me3, a surrogate for chromatin inactivated by polycomb, was reduced after Depsi treatment by 1.4 to 4 fold (Fig. 4D) . Interestingly, Depsi treatment did not seem to have modified nucleosome density (measured by ChIP-PCR of H3/input) on the promoter region of these genes (data not shown). To rule out indirect effects through other chromatin regulators, we measured the expression of DNMT1, DNMT3a, DNMT3b, DNMT3L, DROSHA, DICER, TET1, TET2, and EZH2. We found that most did not change significantly after Depsi treatment (Fig. 3A) . These data show that HDACi directly induced chromatin remodeling and this was associated with gene reactivation from DNA hypermethylated promoters.
Genome wide effects of Depsipeptide on hypermethylated genes
We next investigated on a genomic scale the effect of Depsi on gene reactivation of hypermethylated genes. We combined the data of two independent gene expression microarrays of untreated and Depsi-treated YB5 cells (Fig. S4A ) with whole genome DNA methylation data using Methylation CpG island microarray (MCAM, Fig. S4B (15) . As previously reported by other groups (23, 24) , we found that HDACi increased the expression of 11% of the genes with the same amount of genes being repressed (11%; Fig. S4D ). Whole genome methylation data showed that this colon cancer cell line has more than 330 detectable hypermethylated promoter CGIs (i.e, 6% of the gene promoters on the array; Fig. S4B ). When combining the data of both gene expression and DNA methylation microarrays, we could analyze gene expression and DNA methylation of more than 4,300 genes (Fig. S4C) . In this gene list, 258 genes showed promoter DNA hypermethylation and 8% (21 genes) of these were reactivated following HDACi treatment ( Fig. S4E-F) . Considering that 80-90% of hypermethylated genes in cancer are not expressed in normal tissues and thus lack the appropriate transcription factor for activation, our data suggest that the majority of 'inducible' genes are actually induced by HDACi (25) . By contrast 14% of the unmethylated genes could be reactivated by treatment with Depsi.
DNA methylation is a long-term memory signal for gene silencing
The data described so far demonstrate that rapid activation of a DNA hypermethylated 
cells were cultured post-sorting without drugs and GFP expression was followed for more than 3 months by FACS analysis (Fig. 5A) (Fig. 5A) . We similarly investigated the RNA expression of several hypermethylated genes including GFP (Fig. 5B), MLH1 (Fig. 5C), CDH13 (Fig. S5A) , WIF-1 (Fig. S5B) , and TIMP-3 ( Fig. S5C ) and found that gene expression was activated immediately by treatment with either epigenetic drug, but expression was silenced 2 weeks after Depsi treatment while it was maintained following treatment with 5-AZACdR for up to 9 weeks. Interestingly, other chromatin modifiers such as histone methyltransferase inhibitors were previously shown to induce transient gene activation which returned to the original state upon drug removal (26) . As previously mentioned, methylation levels decreased significantly at GFP (Fig. 5D), MLH1 (Fig. 5E) , CDH13 (Fig. S5D) , WIF-1 (Fig. S5E), TIMP-3 (Fig. S5F) , and LINE-1 (Fig. S5G) .
The gradual loss of GFP expression after 5-AZA-CdR withdrawal was coincided with gradual remethylation of the CMV promoter. Although it has been reported that the p16 CDKN2A/INK4 locus was remethylated after 5-AZA-CdR removal, it has been suggested that the apparent remethylation was due to clonal replacement by a subset of cancer cells that were not affected by 5-AZA-CdR (19, 27) . Cells treated with hypomethylating agents tend to have a longer cell cycle because of the reexpression of growth regulatory signals. Therefore, hypomethylated cell populations can be easily replaced by more rapidly growing methylated populations, which can bias the measurement of DNA methylation (19) . To address this issue, we performed two series of cell sorting experiments using YB5 cells cultured 9 weeks without drug following initial 5-AZA-CdR treatment (Fig. 6A) . The purity of the sorted GFP+ cells exceeded 90% while the GFPcells contained only 0.2% GFP positive cells. Gene expression and DNA methylation analysis of GFP+ and GFP-cells at 9 weeks post-treatment revealed that gene reactivation in GFP+ (Fig. 6B ) was at this late time point associated with an unmethylated promoter region with an average methylation of 15% (Fig. 6C) . GFP-cells exhibited 1000 times less GFP mRNA and a promoter closer to the methylation level of untreated cells with an average methylation of 66% (Fig. 6B-C) . This gene expression pattern was also observed for other TSG such as TIMP-3, CDH13, and MLH1 while their DNA methylation level was reduced in the GFP+ and GFP-cells ( Figure S6A-F In order to eliminate the effect of clonal replacement, we performed cell sorting and single cloning experiments (Fig. 6D) . After clonal expansion of these single clones to obtain enough cells (~2 weeks), we monitored their GFP fluorescence over time (black bars, Fig. 6D ) as compared to sorted cells obtained after 5-AZA-CdR treatment when the purity was ~70% (white bars, Fig. 6D ) and 9 weeks after treatment when the purity exceeded 90% (grey bars, Fig. 6D ). Single cell clones of these GFP+ YB5 cells obtained 9 weeks after 5-AZA-CdR without drugs revealed that 92-97% stably express GFP for up to 6 months post-treatment demonstrating stable epigenetic reprogramming (Fig. 6D) .
Interestingly, the GFP promoter region was completely demethylated in these GFP+ clones (Fig. 6C) . These results clearly show that DNA methylation is the molecular mechanism responsible for long-term gene silencing. Thus, full epigenetic reprogramming and switching from the silent to the expressed state can be accomplished by complete promoter demethylation which is correlated with RNA pol II occupancy (28) . 
Discussion
Early studies have reported that TSG silenced by promoter DNA hypermethylation could be reactivated only after the removal of methylation marks. In these studies, treatment with TSA, an HDACi, could not produce gene reactivation of genes silenced by promoter DNA hypermethylation (6, 7) . Based on these indirect observations, the function of promoter DNA methylation, as a signal for gene silencing, has been considered as a 'lock' for gene expression. However, other studies have reported that hypermethylated genes can be reactivated by TSA and other HDACi without any loss in promoter DNA methylation (9) (10) (11) (12) . These reports put in jeopardy the lock hypothesis which has been the paradigm for more than a decade. Hence, we chose to investigate this issue by looking at the effects of more than 20 different HDACi on reactivation of genes silenced by promoter DNA methylation.
Using the well-characterized YB5 system and other cancer cell lines, we discovered that most of the HDACi-tested could reactivate hypermethylated genes in a dosedependent pattern regarding their chemical class and HDAC affinity. DNA methylation analysis revealed that gene reactivation was generated without any loss of promoter DNA methylation. Methylation levels were carefully assessed before and after treatment by pyrosequencing and bisulfite cloning sequencing since it was reported that HDACi could potentially reduce DNA methylation levels by non-specific mechanisms (16) (17) (18) .
However, our study, as well as others (19) show that methylation levels did not change Author Manuscript Published OnlineFirst on January 4, 2012; DOI: 10.1158/0008-5472. These data have implications for therapeutic intervention. We show that genes silenced by DNA hypermethylation in cancer can be significantly but transiently reactivated through chromatin remodeling without any changes in DNA methylation, and this may be part of the clinical mechanisms of action of HDACi. Moreover, our results provide a molecular explanation for the synergy between decitabine and HDACi (6, 29) 
